Consensus Tenaya Therapeutics, Inc.

Stocks

TNYA

US87990A1060

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:14:02 2026-07-13 pm EDT			5-day change	1st Jan Change
0.8230 ^USD	-5.45%		-5.23%	+15.26%

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI

Evolution of the Average Target: Tenaya Therapeutics, Inc.

Evolution of the Target Price: Tenaya Therapeutics, Inc.

Changes in Analyst Recommendations: Tenaya Therapeutics, Inc.

012f601ae88.ygL6_qPwFZBTt7VIAIgdQ-2IEALSW6CVjFEIfH8Ciy0.gGqwqPykbNMM_9o8Q-RZCt79QFC7LZjB6zBYJhFn5miTSaOr4qhG9mXAwg~758e38e931e09384f97f5e3169a36a4f

Analysts' recommendations: Tenaya Therapeutics, Inc.

25-03-12	Chardan Adjusts Price Target on Tenaya Therapeutics to $9 From $18, Keeps Buy Rating	MT
24-12-17	Leerink Partners Adjusts Tenaya Therapeutics Price Target to $6 From $8, Maintains Outperform Rating	MT
24-06-10	William Blair Starts Tenaya Therapeutics With Outperform Rating	MT
24-05-16	Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating	MT
24-03-20	Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating	MT
23-08-11	Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $17 From $18, Keeps Buy Rating	MT
23-08-10	Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $14 From $13, Keeps Overweight Rating	MT
23-05-12	Chardan Trims Price Target on Tenaya Therapeutics to $23 From $24, Maintains Buy Rating	MT
23-03-09	HC Wainwright Adjusts Price Target on Tenaya Therapeutics to $18 From $25, Maintains Buy Rating	MT
23-03-09	Chardan Cuts Price Target on Tenaya Therapeutics to $24 From $28, Keeps Buy Rating	MT
23-01-24	Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $13 From $15, Maintains Overweight Rating	MT
22-11-11	Chardan Trims Price Target on Tenaya Therapeutics to $28 From $30, Affirms Buy Rating	MT
22-11-08	Canaccord Genuity Starts Tenaya Therapeutics at Buy With $21 Price Target	MT
22-08-11	Chardan Research Trims Tenaya Therapeutics' Price Target to $30 From $31, Maintains Buy Rating	MT
22-06-15	HC Wainwright Starts Tenaya Therapeutics at Buy With $25 Price Target	MT
22-05-17	Morgan Stanley Lowers Tenaya Therapeutics' Price Target to $15 From $19, Maintains Overweight Rating	MT
22-02-01	Morgan Stanley Adjusts Tenaya Therapeutics' Price Target to $19 from $31, Keeps Overweight Rating	MT
21-08-24	TENAYA THERAPEUTICS : Chardan Starts Tenaya Therapeutics at Buy with $37 Price Target on Heart Disease Drugs' Potential	MT
21-08-24	TENAYA THERAPEUTICS : Cowen Starts Tenaya Therapeutics at Outperform	MT
21-08-24	TENAYA THERAPEUTICS : Morgan Stanley Initiates Coverage on Tenaya Therapeutics With Overweight Rating, $31 Price Target	MT
21-08-24	TENAYA THERAPEUTICS : Piper Sandler Starts Tenaya Therapeutics at Overweight With $40 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TENAYA THERAPEUTICS, INC.					+359.56%
	LONZA GROUP AG					+14.2%
	REVOLUTION MEDICINES, INC.					+7.17%
	IQVIA HOLDINGS INC.					+10.48%
	BEONE MEDICINES AG					+38.69%
	CELLTRION, INC.					+46.5%
	ASCENDIS PHARMA A/S					+9.89%
	MEDPACE HOLDINGS, INC.					-16.13%
	EUROFINS SCIENTIFIC SE					+3%
	ICON PUBLIC LIMITED COMPANY					+7.81%
	Average					+48.12%
	Weighted average by Cap.					+16.49%